Pyrogallol Protects Against Influenza A Virus-Induced Lethal Lung Injury Via Nrf2-PPAR-Gamma-HO-1 Signaling Axis Activation

Influenza News: Influenza A virus infections are a significant global health concern due to their ability to cause severe respiratory illnesses, leading to acute lung injury (ALI) and acute respiratory distress syndrome (ARDS). The search for effective treatments against such viral infections especially with the impending H5N1 human outbreak which is likely to occur very soon, has led researchers to explore natural compounds with potential therapeutic properties. One such compound under scrutiny is pyrogallol, a natural polyphenol known for its diverse pharmacological activities, including anti-inflammatory and antioxidant effects. This Influenza News report delves into the mechanisms through which pyrogallol exhibits protective effects against Influenza A virus-induced lung injury based on a study by researchers from the Integrated Hospital of Traditional Chinese Medicine, Southern Medical University, Guangzhou-China, The People's Hospital of Gaozhou-China, Guangzhou Laboratory-, China and the First Affiliated Hospital of Guangzhou Medical University-China.

 Pyrogallol Protects Against Influenza A Virus-Induced Lethal Lung Injury 

Understanding Influenza A Virus Infections
Influenza A virus infections are characterized by their impact on the respiratory system, ranging from mild symptoms to severe respiratory distress. The progression to ALI and ARDS can be rapid, leading to increased mortality rates. The excessive inflammation triggered by viral infections plays a pivotal role in exacerbating the severity of the disease. Current treatments often combine antiviral agents with immunomodulators to mitigate the overwhelming immune response and reduce mortality rates. However, the search for novel agents that can effectively target viral factors and attenuate inflammation is ongoing.
 
The Role of RIG-I Signaling and Type I IFNs in Influenza Pathogenesis
Understanding the molecular pathways involved in influenza pathogenesis is crucial for targeted interventions. Retinoic acid-inducible gene-I (RIG-I) signaling plays a pivotal role in antiviral defense but can also contribute to exaggerated inflammatory responses, termed "cytokine storms." Similarly, type I interferons (IFNs) are key players in antiviral immunity but can exacerbate inflammation and cell death, leading to severe lung damage.
 
Exploring Pyrogallol's Pharmacological Properties
Pyrogallol, a polyphenol phytochemical compound found in fruits and herbs, has garnered attention for its wide-ranging pharmacological activities. These include anti-inflammatory, antioxidant, and antiviral properties. Pyrogallol's mechanism of action involves targeting various molecular pathways, such as Nrf2, p38 MAPK, and p53. Previous studies have demonstrated its efficacy in inhibiting inflammatory responses and promoting cell survival. However, its specific effects against Influenza A virus infections and associated lung injuries require further investigation.
 
Mechanisms of Pyrogallol's Protective Effects
Recent research has shed light on the protective mechanisms of pyrogallol against Influenza A virus-induced lung injury. One key pathway involves the activation of nuclear factor erythroid-2-related factor 2 (Nrf2) and peroxisome proliferator-activated receptor gamma (PPAR-γ), which leads to the synthesis of heme oxygenase-1 (HO-1). This signaling axis plays a crucial role in mitigating oxidative stress and inflammation induced by viral infections. Pyrogallol's ability to activate Nrf2 and PPAR-γ enhances the expression of HO-1, which in turn suppresses excessive proinflammatory responses and cell death.
 
Unraveling the Protective Mechanisms of Pyrogallol
Alleviating Influenza A Virus-Induced ALI: In animal models infected with H1N1 influenza A virus, pyrogallol treatment reduced lung inflammation, improved lung pathology, and increased survival rates. It also showed antiviral activity against multiple influenza strains and mitigated inflammatory cytokine levels induced by the virus.
 
The various mechanistic actions of Pyrogallol in helping with Influenza A infections include:
 
-Activating Nrf2–PPAR-γ–HO-1 Signaling Axis: Pyrogallol's protective effects were linked to the activation of Nrf2 and PPAR-γ, which enhanced the synthesis of heme oxygenase-1 (HO-1), an antioxidant enzyme crucial in combating oxidative stress and inflammation.
 
-Suppressing RIG-I–NF-κB Signaling: Pyrogallol inhibited the aberrant activation of RIG-I–NF-κB signaling induced by the virus, reducing the production of proinflammatory mediators responsible for severe lung damage.
-Reducing Cell Death Pathways: Pyrogallol attenuated various forms of cell death (apoptosis, necrosis, ferroptosis) triggered by the virus, further protecting lung tissue integrity and function.
 
-Mitigating IFN-β-Mediated Proinflammatory Responses: Pyrogallol inhibited the amplification of proinflammatory reactions triggered by IFN-β, a cytokine involved in immune responses to viral infections, thereby reducing excessive inflammation and apoptosis.
 
Experimental Evidence Supporting Pyrogallol's Efficacy
In vivo studies utilizing animal models infected with H1N1 Influenza A virus have demonstrated pyrogallol's protective effects. Treatment with pyrogallol resulted in reduced lung injury, decreased inflammatory markers, and improved survival rates among infected animals. These findings highlight the therapeutic potential of pyrogallol in mitigating the detrimental effects of viral infections on the respiratory system.
 
Pyrogallol's Impact on Cellular Signaling Pathways
Pyrogallol's protective effects are mediated through its modulation of various cellular signaling pathways. It inhibits aberrant retinoic acid-inducible gene-I-nuclear factor kappa B (RIG-I–NF-κB) signaling, thereby reducing the production of proinflammatory cytokines and chemokines. Additionally, pyrogallol suppresses cell death pathways, including apoptosis, necrosis, and ferroptosis, which are triggered by viral infections. These effects contribute to its overall ability to alleviate lung injury associated with Influenza A virus.
 
Role of HO-1 in Pyrogallol-Mediated Protection
The induction of heme oxygenase-1 (HO-1) emerges as a critical factor in pyrogallol's protective mechanism. HO-1 exerts anti-inflammatory and cytoprotective effects by metabolizing heme into biologically active byproducts. Inhibition of HO-1 activity diminishes pyrogallol's ability to suppress inflammatory responses and cell death pathways, underscoring the importance of HO-1 induction in mediating pyrogallol's protective effects against viral infections.
 
Pyrogallol's Potential Clinical Implications
The promising results obtained from preclinical studies warrant further exploration of pyrogallol as a potential therapeutic agent for Influenza A virus infections. Clinical trials evaluating its safety and efficacy in human subjects infected with Influenza A virus strains could provide valuable insights into its clinical utility. Additionally, combination therapies incorporating pyrogallol with existing antiviral agents and immunomodulators may enhance treatment outcomes and reduce disease severity.
 
Conclusion
In conclusion, pyrogallol demonstrates significant potential as a protective agent against Influenza A virus-induced lung injury. Its ability to modulate cellular signaling pathways, activate antioxidant enzymes like HO-1, and suppress inflammatory responses makes it a promising candidate for further investigation. Future research efforts should focus on elucidating the precise molecular mechanisms underlying pyrogallol's effects and translating these findings into clinical applications for combating severe respiratory infections.
 
The study findings were published in the peer reviewed journal: MedComn (Wiley Journals).
https://onlinelibrary.wiley.com/doi/10.1002/mco2.531
 
For the latest Influenza News, keep on logging to Thailand Medical News.